Cardiovascular Risk in Pancreatic Cancer: A Meta-Analysis of 197 Studies

Read full text Summarise with VIRAT
Authors: Jázmin Németh, Jimin Lee, Orsolya Eperjesi, Endre Botond Gagyi, Zoltán Bánfalvi, Veronika Lillik, Ioana Creangă-Murariu, Réka Tóth, Eszter Ágnes Szalai, Mahmoud Obeidat, Szilárd Váncsa, Ștefania Bunduc
+1 more Péter Jenő Hegyi
Cited by: 0
References: 71

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Background/Objectives: Cardiovascular diseases (CVDs) frequently limit the feasibility and effectiveness of cancer treatment. However, CVD burden has not been comprehensively described in pancreatic cancer. In our systematic review and meta-analysis, we evaluated the prevalence and incidence of CVDs in pancreatic ductal adenocarcinoma (PDAC). Methods: We conducted the systematic search in PubMed, EMBASE, and CENTRAL on 5 February 2024. Studies reporting the prevalence or incidence of CVDs in PDAC were included. Subgroup analyses were performed based on cancer stage and treatment type. Pooled proportions with the 95% confidence interval (CI) were calculated using a random-effects model. (PROSPERO: CRD42023482295). Results: We included 197 articles. At PDAC diagnosis, non-thrombotic cardiovascular diseases (NT-CVDs) were as prevalent as in the general population: hypertension in 33% (CI: 27–40%), ischemic heart disease in 6% (CI: 3–12%), and heart failure, arrhythmia, and stroke each in 2–3%. Their incidence during treatment remained low (1–10%). Thrombotic events, excluding pulmonary embolism, were present in 11% (CI: 7–15%) at diagnosis, with an incidence of 8–10% regardless of stage or treatment. Pulmonary embolism affected 3% at diagnosis and occurred at a similar rate during treatment. Conclusions: Thromboembolic events are common in PDAC and occur both at diagnosis and during follow-up. Their incidence remains stable across treatment modalities and disease stages, suggesting that the tumor itself is the primary driver of thrombotic risk. The prevalence of NT-CVDs in PDAC is comparable to that in the general population and shows minimal variation across cancer stages or treatment modalities.

Fields of Study & Subjects

Pancreatic and Hepatic Oncology Research Chemotherapy-induced cardiotoxicity and mitigation Venous Thromboembolism Diagnosis and Management

Publication details

Journal / source
Cancers
Volume
18
Issue
7
Pages
1108–1108
Publication date
29 March 2026
Language
EN